Telomeres, tissue repair, GH restoration, and the anti-aging research landscape
Last updated: April 2026 | Research use only — not medical advice
The peptides discussed here are research chemicals studied for biological aging mechanisms. None are FDA-approved anti-aging treatments. Longevity claims are based on preclinical and early-phase human research, not FDA-reviewed clinical trials. This is an educational overview of the research landscape. Consult a qualified physician before using any of these compounds.
Research peptides don't work through a single "anti-aging" mechanism. Different peptides target different underlying biological processes associated with aging. Understanding which pathway a peptide acts on helps evaluate whether it's relevant to a given research goal.
Epithalon is the most directly longevity-focused research peptide in this guide. It activates telomerase — the only known peptide to do so at physiological doses. Its developer, Dr. Vladimir Khavinson, studied it over four decades and conducted a 12-year longitudinal study in elderly humans that reported significantly reduced all-cause mortality in treated subjects.
Key research findings: In vitro telomerase activation in human fetal cells. Reduction of reactive oxygen species. Normalization of melatonin and cortisol rhythms in elderly subjects. Life extension in animal models. The 12-year human mortality data, while preliminary and methodologically limited by modern standards, remains one of the longest longitudinal datasets for any research peptide.
Unique feature: Epithalon is used in cycles (5–10mg/day × 10–20 days, 1–2× per year) rather than continuously — reflecting both Khavinson's original protocols and the nature of telomere biology research.
→ Full Epithalon Price Guide (5mg from $28.99)GHK-Cu is uniquely positioned in the longevity research space because it is naturally produced by the human body — and its plasma levels decline significantly with age (from ~200 ng/mL at age 20 to ~80 ng/mL at age 60). This age-related decline overlaps with declining skin integrity, slower wound healing, and reduced tissue maintenance.
What makes GHK-Cu remarkable: Research by Loren Pickart's group identified GHK-Cu as influencing the expression of over 4,000 human genes — essentially a broad-spectrum biological reset signal. Genes upregulated include those involved in collagen synthesis, antioxidant defense, tissue remodeling, and anti-inflammatory pathways. Genes downregulated include those associated with aging, inflammation, and cancer progression.
Practical context: GHK-Cu is already used in cosmetic products for skin anti-aging at topical doses. Research-grade GHK-Cu allows higher-concentration systemic research at lower cost per mg than most other peptides.
→ Full GHK-Cu Price Guide (50mg from $45.99)BPC-157 is among the most extensively researched peptides in animal models, with a remarkable breadth of tissue repair evidence: tendon and ligament healing, gut barrier integrity, bone repair, nerve repair, cardiovascular protection, and wound healing. It is derived from a partial sequence of body protection compound found in human gastric juice.
Longevity angle: The aging body loses regenerative capacity — healing slows, gut integrity declines, and accumulated tissue damage builds. BPC-157's broad repair-stimulating profile makes it relevant to the "maintenance and repair" dimension of longevity research, even without direct telomere or GH axis effects. Its angiogenesis (new blood vessel) research is particularly notable.
Evidence quality note: BPC-157 has an unusually strong animal model record, but human clinical trial data is limited. Phase 1/2 trials for inflammatory bowel disease have been conducted. This gap between animal data and human trials is smaller than for some other peptides, but human data should be the benchmark.
→ Full BPC-157 Price Guide (5mg from ~$33)TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide involved in cell migration, angiogenesis, and tissue repair. Its mechanism (promoting actin polymerization and cell motility) is distinct from BPC-157, making the two complementary in tissue repair research protocols. Age-related decline in regenerative capacity is partly attributed to reduced Thymosin Beta-4 signaling.
TB-500 has been studied for cardiovascular repair (including cardiomyocyte survival post-ischemia), wound healing, and musculoskeletal recovery. The cardiovascular research is particularly interesting from a longevity perspective, given that cardiovascular disease remains the leading age-related cause of death.
→ Full TB-500 Price Guide (10mg from $40.99)Somatopause is the gradual, age-related decline in growth hormone pulsatility that begins in the third decade of life and accelerates with each subsequent decade. By age 60, most people produce only 25–30% of the GH they produced at 20. This decline is associated with increased fat mass, decreased lean mass, slower healing, reduced energy, and impaired sleep quality.
Sermorelin is the most historically validated GH-stimulating peptide for age-related GH decline. As a GHRH analogue, it stimulates the pituitary to increase its own GH production — preserving the natural feedback loop rather than introducing exogenous HGH. It was previously FDA-approved for pediatric GH deficiency (Geref), giving it a more developed clinical record than most research peptides.
In aging research contexts, Sermorelin has been studied for improving body composition, sleep quality (GH is released primarily during deep sleep), bone density, and energy. Its short half-life (~10–20 minutes) means it needs frequent dosing or combination with a GHRP, but this also means the pulsatile, physiological nature of GH release is preserved.
→ Full Sermorelin Price Guide (2mg from $25.95)CJC-1295 combined with Ipamorelin is the most studied GHRH/GHRP combination for age-related GH decline. CJC-1295 (especially without DAC / Mod GRF 1-29) acts like a stronger, longer-lasting Sermorelin, while Ipamorelin adds the GHRP component that amplifies the GH pulse 5–10× beyond what either peptide produces alone. The combination is considered to produce the most physiologically natural and potent GH pulse achievable without pharmaceutical HGH.
For longevity protocols, the typical research approach uses low doses (100–200mcg of each, 3–5× per week) to restore something approximating youthful GH pulsatility rather than supraphysiological GH levels.
→ Full CJC-1295 / Ipamorelin Price Guide| Peptide | Primary Longevity Mechanism | Human Evidence | Typical Protocol | Cost Range |
|---|---|---|---|---|
| Epithalon | Telomerase activation, telomere length | 12-year human mortality study (Khavinson) | 10mg/day × 10–20 days, 1–2×/year | $50–$300/cycle |
| GHK-Cu | Gene expression remodeling, collagen, antioxidant | Human cosmetic trials; plasma level studies | 50–100mg/month (subcutaneous) | $33–$100/month |
| BPC-157 | Tissue repair, angiogenesis, gut health | Limited Phase 1/2 IBD trials; strong animal data | 250–500mcg/day × 6–12 weeks | $40–$120/month |
| TB-500 | Cell migration, angiogenesis, cardiac repair | Animal models; limited human data | 2–5mg 2×/week (loading), then 1×/week | $60–$120/month |
| Sermorelin | GH restoration, somatopause reversal | Phase 2/3 trials (pediatric GHD) | 0.2–0.3mg/day subcut at bedtime | $50–$150/month |
| CJC-1295 + Ipamorelin | Synergistic GH restoration | Phase 1 (CJC-1295); animal + Phase 1 (Ipamorelin) | 100mcg each 3–5×/week | $60–$120/month combined |
| Selank | Neuroinflammation, BDNF, immune modulation | Russian clinical trials; drug approved in Russia | 250–500mcg/day (intranasal or subcut) | $25–$50/month |
Because different peptides address different aging mechanisms, some researchers combine multiple compounds in "longevity stacks" — targeting several pathways simultaneously. The most common research approaches combine peptides that don't compete with each other mechanistically.
Multi-peptide protocols significantly increase complexity and potential for unforeseen interactions. The individual safety profiles of each peptide are not well-established in humans; combining multiple compounds without medical supervision amplifies this uncertainty. This information is provided for research context only. Any therapeutic use requires physician oversight.
Long-term safety data for most research peptides is limited. Epithalon has the most extensive longitudinal human data, with Khavinson's 12-year study showing no adverse effects. GHK-Cu is an endogenous peptide with a strong cosmetic safety record. BPC-157 and TB-500 have excellent animal safety profiles. GH peptides (Sermorelin, CJC-1295) have the most developed human safety records due to clinical trials. None of these have been evaluated in large-scale human trials specifically for long-term longevity use, so caution and medical supervision are appropriate.
Epithalon is the only research peptide with evidence for direct telomerase activation at the cellular level — targeting what many consider the fundamental biological clock of aging. Most other longevity peptides work on maintenance and repair rather than the underlying aging mechanism itself. The 12-year human data from Khavinson's group is also unique — no other research peptide has comparable longitudinal human outcome data, however preliminary it may be by current standards. Epithalon's cyclic use protocol (unlike the daily dosing of most peptides) also distinguishes it practically.
Genomic analysis by Loren Pickart's research group found GHK-Cu influences expression of approximately 4,000 human genes. Upregulated gene categories include: collagen and elastin synthesis, antioxidant enzymes (superoxide dismutase, catalase), tissue repair factors, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and anti-inflammatory cytokines. Downregulated gene categories include those associated with inflammation, cancer progression, and cellular senescence markers. The breadth of this gene expression effect is unusual for a peptide this small (just 3 amino acids + copper ion) and suggests it may function as a broad biological "maintenance mode" signal.
Growth hormone is secreted in pulses primarily during deep sleep, stimulated by the hypothalamic GH-releasing hormone (GHRH). With age, GHRH secretion declines and somatostatin (GH-inhibiting hormone) activity increases — resulting in fewer and smaller GH pulses. This isn't pathological in the same way as disease; it's a normal aging process. The consequences, however, are significant for quality of life: increased central fat deposition, decreased lean mass, reduced bone density, slower healing, worse sleep quality, and lower energy. GH peptides attempt to restore more youthful GH pulsatility by addressing the GHRH deficit (GHRH analogues) or by directly triggering larger GH pulses (GHRPs like Hexarelin, Ipamorelin) through the ghrelin receptor pathway.
This is an emerging research area. Some longevity researchers are interested in GLP-1 agonists (semaglutide, tirzepatide) not just for weight loss but for their emerging evidence on neurodegeneration, cardiac protection, and anti-inflammatory effects — mechanisms that overlap with aging biology. Emerging data suggests GLP-1 agonists may reduce risk of Alzheimer's disease, Parkinson's disease, and other age-related conditions beyond their metabolic effects. Combined protocols using GLP-1 agonists alongside longevity-specific peptides (Epithalon, GHK-Cu) represent a frontier of research that lacks established protocols or safety data.
🔬 NAD+ and Longevity: NMN (nicotinamide mononucleotide) addresses the NAD+ decline axis that many longevity researchers consider foundational — complementary to the peptide pathways covered here. See our NMN / NAD+ Price Guide →